Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769169 | 0.90 | HRH3 (0.53) | HRH3L3MBTL1L3MBTL3HTTKDM4E | |
| SCHEMBL3767732 | 0.90 | HRH3 (0.53) | HRH3L3MBTL1L3MBTL3HTTKDM4E | |
| SCHEMBL3780686 | 0.87 | ALDH1A1 (0.53) | HRH3MEN1KMT2AHTTKDM4E | |
| SCHEMBL3774012 | 0.87 | L3MBTL1 (0.61) | HRH3MEN1KMT2AL3MBTL1L3MBTL3 | |
| SCHEMBL3769162 | 0.85 | HTT (0.70) | HRH3L3MBTL1L3MBTL3HTTKDM4E | |
| SCHEMBL3762910 | 0.85 | ALDH1A1 (0.54) | HRH3KMT2AL3MBTL1L3MBTL3ALDH1A1 | |
| SCHEMBL3774758 | 0.85 | HRH3 (0.63) | HRH3KMT2AL3MBTL1L3MBTL3KDM4E | |
| SCHEMBL3770293 | 0.84 | HRH3 (0.51) | HRH3MEN1KMT2AL3MBTL1L3MBTL3 | |
| SCHEMBL3768037 | 0.84 | HRH3 (0.55) | HRH3L3MBTL1L3MBTL3KDM4EALDH1A1 | |
| SCHEMBL3762944 | 0.83 | PARP1 (0.49) | HRH3MEN1KMT2AHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | HRH3 2/4885MEN1 3270/4885KMT2A 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.